RxDoctor Payments Data

Patricia Powers

Family · Greenbrier, TNNPI 1396012399

Payments from drug & device makers

$5,602in general payments, 2019–2025

Across 328 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$900
  • AbbVie$657
  • AstraZeneca$430
  • Pfizer$292
  • Lilly USA, LLC$261
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$5,602100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,602 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$30,402
Medicare patients
115
Services billed
1,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$95,805
TrulicityDulaglutide51$59,401
EliquisApixaban60$48,122
FarxigaDapagliflozin Propanediol37$38,225
JardianceEmpagliflozin44$35,215
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$35,142
GemtesaVibegron21$25,490
MounjaroTirzepatide21$22,028
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog34$15,460
MyrbetriqMirabegron26$13,382
JanuviaSitagliptin Phosphate18$12,825
Aimovig AutoinjectorErenumab-Aooe16$12,095
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$11,470
Combivent RespimatIpratropium/Albuterol Sulfate12$11,118
VascepaIcosapent Ethyl23$10,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,114$95,80569 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$261$83,26389 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$430$52,57969 claims
PfizerEliquis$292$48,12260 claims
Boehringer IngelheimJardiance, Combivent Respimat$65$46,33456 claims
GSKTrelegy Ellipta, Breo Ellipta$107$43,49945 claims
Sumitomo Pharma America, Inc.Gemtesa$117$25,49021 claims
Astellas Pharma US IncMyrbetriq$79$13,38226 claims
AbbVieLinzess$657$7,99813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.

Other family in Greenbrier

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →